NASDAQ$RGEN
Repligen Corp · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported record quarterly revenue with strong margin expansion.
Repligen reported a strong third quarter in 2020, achieving a record quarterly revenue of $94.1 million, driven by a 35% year-over-year growth and a 31% organic growth. COVID programs accounted for approximately 14% of revenue during the quarter, contributing to approximately 55% of revenue growth. The company also updated its full-year 2020 financial guidance, raising revenue expectations to $348-$352 million.
- Repligen reported record quarterly revenue of $94.1 million, with a 35% year-over-year increase and 31% organic growth.
- Gross margin (GAAP) was 57.9%, an increase of 3.1 points, and adjusted gross margin (non-GAAP) was 58.0%, an increase of 1.9 points compared to third quarter of 2019.
- Operating margin (GAAP) was 22.3%, an increase of 10.8 points, and adjusted operating margin (non-GAAP) was 28.6%, an increase of 6.8 points compared to the third quarter of 2019.
- The company raised revenue guidance to $348-$352 million and overall revenue growth to 29%-30% for full year 2020.
Headline financials
Revenue & EPS history
Repligen · Revenue · Quarterly
$94.1M
Revenue by segment
Repligen · $141M total across 2 segments · Q3 2023
- Product Revenue$141M—100.0%
- Royalty and Other$36—0.0%
Forward guidance
Repligen updated its financial guidance for the fiscal year 2020, projecting total revenue in the range of $348-$352 million and adjusted fully diluted EPS in the range of $1.41-$1.45.
Tailwinds
- Total revenue is projected to be in the range of $348-$352 million, an increase from our previous guidance of $332-$340 million.
- Overall revenue growth of 29%-30%, with organic revenue growth in the range of 23%-24%.
- Gross margin is expected to be in the range of 57.5%-58.0% on both a GAAP and non-GAAP basis, compared to our previous guidance of 56.5%-57%.
- Income from operations is expected to be in the range of $66-$68 million on a GAAP basis, an increase from our previous guidance of $59-$62 million.
- Adjusted income from operations (non-GAAP) is expected to be in the range of $91-$93 million, an increase from our previous guidance of $81-$84 million.
Headwinds
- The guidance does not include the impact of our proposed acquisition of ARTeSYN Biosolutions, which is expected to close during the fourth quarter of 2020.
- The guidance also excludes the impact of potential additional acquisitions and future fluctuations in foreign currency exchange rates.
- $9.2 million estimated acquisition and integration expenses.
- Expected inventory step-up charges of $0.2 million related to the acquisitions of Engineered Molding Technology and Non-Metallic Solutions.
- $15.8 million estimated intangible amortization expense.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+2.6%
Avg return
Earnings day
+3.4%
Avg return
5 days after
+4.4%
Avg return
30 days after
59%
36 / 61 earnings
Positive
+22.1%
Q3 2018
Best reaction
-23.0%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.1% | -7.8% | -2.7% | |
| Q4 2025 | +1.4% | -4.9% | -15.5% | |
| Q3 2025 | -5.9% | -7.5% | +6.3% | |
| Q1 2025 | -2.9% | -1.5% | -14.8% | |
| Q4 2024 | +7.9% | +7.1% | -7.1% | |
| Q3 2024 | +7.9% | -10.6% | +11.8% | |
| Q2 2024 | +21.3% | +17.2% | +9.2% | |
| Q1 2024 | +1.3% | +2.3% | -9.2% | |
| Q4 2023 | -3.2% | -4.0% | -0.9% | |
| Q3 2023 | +15.1% | +31.7% | +37.7% | |
| Q2 2023 | +1.1% | +2.5% | +5.2% | |
| Q1 2023 | +6.4% | +4.3% | +8.8% | |
| Q4 2022 | +3.2% | -2.7% | -10.0% | |
| Q3 2022 | -6.0% | -4.5% | +3.1% | |
| Q2 2022 | +13.1% | +15.9% | +0.6% | |
| Q1 2022 | +7.8% | +11.4% | +19.3% | |
| Q4 2021 | -1.8% | -1.4% | +4.0% | |
| Q3 2021 | +7.2% | +11.7% | +5.5% | |
| Q2 2021 | +14.2% | +19.3% | +32.4% | |
| Q1 2021 | -6.4% | -9.8% | -15.6% | |
| Q4 2020 | +0.3% | +7.4% | -11.1% | |
| Q3 2020 | +8.1% | +0.0% | +0.8% | |
| Q2 2020 | +8.7% | +12.8% | +8.2% | |
| Q1 2020 | +6.7% | +11.9% | +5.0% | |
| Q4 2019 | -10.1% | -22.2% | -18.7% | |
| Q3 2019 | +9.9% | +6.1% | +15.1% | |
| Q2 2019 | -4.0% | -3.2% | -1.7% | |
| Q1 2019 | +2.5% | -0.2% | +11.5% | |
| Q4 2018 | -0.2% | +1.0% | -0.2% | |
| Q3 2018 | +22.1% | +25.2% | +19.3% | |
| Q2 2018 | -1.0% | +2.0% | +14.2% | |
| Q1 2018 | +5.1% | +10.2% | +14.9% | |
| Q4 2017 | +9.2% | +9.5% | +6.2% | |
| Q3 2017 | -7.1% | -13.0% | -4.9% | |
| Q2 2017 | +1.3% | +4.4% | +6.1% | |
| Q1 2017 | +5.2% | +6.3% | +11.7% | |
| Q4 2016 | +6.3% | +6.4% | +13.6% | |
| Q3 2016 | -4.1% | -1.1% | +10.0% | |
| Q2 2016 | -0.6% | -1.1% | +3.9% | |
| Q1 2016 | +2.1% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | -23.0% | — | — | |
| Q2 2015 | -0.2% | — | — | |
| Q1 2015 | +16.9% | — | — | |
| Q4 2014 | +14.9% | — | — | |
| Q3 2014 | -6.6% | — | — | |
| Q2 2014 | -3.6% | — | — | |
| Q1 2014 | +5.0% | — | — | |
| Q4 2013 | -8.8% | — | — | |
| Q3 2013 | +8.8% | — | — | |
| Q2 2013 | -0.1% | — | — | |
| Q1 2013 | +2.9% | — | — | |
| Q3 2010 | -5.0% | — | — | |
| Q4 2012 | +5.8% | — | — | |
| Q3 2012 | +10.2% | — | — | |
| Q2 2012 | -0.4% | — | — | |
| Q4 2010 | -1.5% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q2 2011 | -0.1% | — | — | |
| Q1 2011 | -0.9% | — | — | |
| Q4 2011 | -0.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro